(Updates throughout with deals, approvals and supply details)
May 21 (Reuters) - At least 181 countries have started vaccinating against COVID-19. The following table shows the status of available vaccines and
details of emergency use authorizations, efficacy rates, and supply and production pledges.
COMPANY State of play Efficacy rate Production Pledges Doses Committed
Pfizer Inc Vaccine being administered in Two doses of the shot cut Pfizer expects to produce 3 bln European Commission on May 20 signs third
and countries including Bahrain, symptomatic COVID-19 vaccine doses in 2021, 4 bln in contract for an additional 1.8 bln doses of
BioNTech SE Canada, Chile, Israel, Japan, cases by 94% 2022 vaccine. The deal reserves doses on behalf of
22UAy.F, South Africa, South Korea, the all EU member states between end 2021 to 2023.
United Kingdom and the United Real-world data from European Medicines Agency approves The two companies have already committed to
States Israel suggests vaccine increase in batch size and supplying 600 mln shots to EU
is 94% effective in associated process scale-up at
U.S. FDA authorizes vaccine preventing asymptomatic Belgium vaccine manufacturing site U.S. - 200 mln+ option for 400 mln more; 300
for adolescents aged 12-15, infections, meaning it mln doses to be delivered by July end
with immunization beginning in could reduce transmission
mid-May UK - 100 mln doses Japan - 144 mln doses South Korea - 66 mln doses Turkey- 60 million additional doses, bringing total number of doses to 120 mln
Moderna Inc Vaccine being administered in Late-stage study showed To supply 34 mln doses of its 132 million doses have been delivered globally
countries including Canada, its vaccine was 94.1% COVID-19 vaccine this year, and
Singapore, Switzerland, United effective with no serious 466 mln next year to global COVAX U.S. - 300 mln
Kingdom, United States, South safety concerns. Dosing programme
Korea, Japan and several begins for trial in EU - 310 mln
European Union countries children aged six months To boost manufacturing capacity to
to less than 12 years. make up to 3 bln doses in 2022; UK - 17 mln
increasing 2021 vaccine production
expectations to between 800 mln Japan - 50 mln, to be distributed by Takeda
and 1 bln shots Canada - 650,000 doses by April-end, down from expected 1.2 mln South Korea - 40 mln doses, timeline unspecified Brazil - In talks
Johnson & Vaccine use resumes after a 66% effective at Establishing a vaccine supply More than 830 mln doses to at least six
Johnson pause in United States, Europe preventing moderate to network in which 10 manufacturing countries
and other countries when severe COVID-19 in a sites would be involved in
authorities checked for a 44,000 person global production of the vaccine, in U.S. - 100 mln in H1 2021 + 200 mln more under
possible link to rare clots trial addition to its Netherlands plant subsequent agreement
post vaccination Pledges to supply African Union UK - 30 mln + option for up to 22 mln more
(AU) with up to 400 mln doses
beginning in Q3 EU - 200 mln + 200 mln additional Weekly shipments in U.S. drop in GAVI Vaccine Alliance- 200 mln doses
early April after FDA identifies
issues at a manufacturing plant India - Vaccine maker Biological E. looking to contract-manufacture 600 mln doses annually AstraZeneca Vaccine use resumes after a The vaccine was found to Says on track to deliver 200 mln More than 15 countries and groups for over 1
& pause in United States, Europe be 79% effective in doses a month from April bln doses
Oxford and other countries when preventing symptomatic U.S. - 300 mln
University authorities checked for a illness in a large trial Co earlier committed to making
possible link to rare clots in Chile, Peru and United "best reasonable efforts" to UK - 100 mln, including 10 mln made by India's
post vaccination States when given two deliver 180 mln vaccine doses to Serum Institute
doses at a four-week EU in Q2, for a total of 300 mln
EU advises against second shot interval from December to June, but said in EU - At least 300 mln + 100 mln additional
of vaccine for anyone who has March it would deliver only a Sweden donates 1 mln shots to COVAX
had blood clots with low blood British study finds two third of that by the end of June,
platelets after receiving the doses may be 85% to 90% of which about 70 mln would be in Mexico - Nearly 1.2 mln doses arrived from
first. effective against Q2 - prompting a European Union U.S. on May 21
symptomatic disease, but lawsuit
cautions not enough data Serum Institute of India to ramp
yet to be conclusive up monthly capacity to 100 mln
doses by end of July, from up to
70 mln
Sinovac Approved in China, Indonesia, Vaccine found to have an Reaches 2 billion doses annual About 249 mln doses to at least six countries.
Biotech Ltd Brazil, Turkey, Thailand, efficacy rate ranging capacity Indonesia - 125 mln doses
Malaysia and the Philippines from about 50% to 90% in Brazil - 100 mln doses
studies More than 300 mln doses of Turkey - 50 mln doses
vaccine, named CoronaVac, have Chile - 60 mln doses
WHO says vaccine been delivered globally as of
efficacious in preventing end-April
COVID-19 in adults under
60, but some quality data
on risk of serious
adverse effects lacking Indonesian study finds
vaccine was 98% effective
at preventing death and
96% effective at
preventing hospitalisation among
inoculated Indonesian
medical staff Gamelya Over two dozen countries have 91.6% effective in 50 mln doses to Turkey, to start Supply deals with over 13 countries including
Research approved Russia's Sputnik V preventing people from arriving in May 2021 India, Brazil, Algeria, Bolivia and Argentina
Institute vaccine developing COVID-19 South Korea's Huns Global Co Ltd Mexico - in talks for 24 mln doses
to lead consortium to produce 100
mln doses per month; last year, Brazil - to buy 10 mln doses to be delivered
another Korean biotech firm GLG during Q2
Raphael signed a deal to make 150
mln doses per year India's Gland Pharma to make up to
252 mln doses, and Hetero pharmacy
to produce over 100 mln doses.
India also started getting first
doses from Russia on May 1 Brazilian pharmaceutical company
União Quimica completed production
of its first batch of 100,000
Sputnik V vaccines
CanSino Approved in China, Pakistan, Success rate of 68.83% at It aims to have 500 million doses Mexico - 10 mln-35 mln doses
Biologic Inc Hungary and Mexico. Brazil preventing all of production capacity by end-2021 Pakistan - Private co in Pakistan to receive
reviewing emergency use symptomatic disease 310,000 doses in the next two months
request Proposed supplying “tens of million of doses” of single-dose vaccine to global vaccine sharing scheme COVAX between late 2021 and end of 2022
China National China, Iraq, Pakistan, Efficacy was pegged at Co says it has annual capacity of Hungary - 5 mln doses
Pharmaceutical Morocco, Argentina and Hungary 79.34% by the company. 1 billion doses Indonesia - At least 2 mln
Group Corp's approved the shot developed by ] Argentina - 1 mln
(Sinopharm) an affiliate of Sinopharm Senegal - 200,000 doses
Beijing unit WHO approves vaccine for Morocco - 1 mln doses
emergency use Zimbabwe - 1.8 mln doses Bolivia - 500,000 doses Pakistan- 1.2 mln doses Czech Republic - In talks with China Egypt - 650,000 doses delivered, of which some 600,000 were a gift from Beijing.
Bharat Biotech The Indian-made vaccine has Interim analysis based on To ramp up production by 200 India - 10 mln doses
been granted emergency use 43 cases showed 81% million doses per year by the
authorization in its domestic efficacy in preventing fourth quarter
market, Nepal and Zimbabwe symptomatic COVID-19 Novavax Inc Expands late-stage study to 96% effective in Pushes back regulatory filings for At least 620 mln doses to nine countries.
NVAX.O include up to 3,000 preventing cases caused the authorization of vaccine to Q3 Japan - expects distribution to begin in late
adolescents aged 12 to 17 by the original version from Q2; does not expect to hit 2021 or early 2022
of the coronavirus, and production target of 150 mln shots COVAX - To start shipping doses in Q3 2021;
Europe has begun rolling 86% effective against a per month until Q4, later than will manufacture and ship 350 mln shots
review, company has applied to more contagious variant previous forecast of sometime in itself, India's Serum Institute to provide
Canada for review in late-stage UK trial Q3 rest of the 1.1 bln shots to COVAX Late-stage study under way in
the U.S. and Mexico. Expects to report U.S.
late-stage vaccine data
in Q2
Medicago Canadian health regulator Mid-stage data showed Not disclosed Not disclosed
accepted application for a strong antibody response
real-time review of vaccine, against the virus
which is in a late-stage study
in combination with a booster
from GlaxoSmithKline Sinopharm Approved in China for public Efficacy rate of 72.51%, Co has a capacity to produce 100 Two COVID-19 vaccines from Sinopharm units
affiliate use on Feb. 25 according to interim million doses a year have hit a combined 100 mln doses of supply
Wuhan analysis of late-stage around the world
Institute Of trial data
Biological Products' vaccine (Reporting by Manas Mishra, Vishwadha Chander, Amruta Khandekar, Dania Nadeem, Mrinalika Roy, Trisha Roy, Muvija M, Pushkala Aripaka and Anuron Mitra in
Bengaluru; Editing by Anil D'Silva, Arun Koyyur, Shailesh Kuber and Ramakrishnan M.)
我们的标准: 汤森路透“信任原则”